Maternal Therapy With TAF Versus TDF to Prevent Vertical Transmission of Hepatitis B

December 25, 2020 updated by: New Discovery LLC

Real World Study of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate to Prevent Vertical Transmission of Hepatitis B in Mothers With High Viral Load

Immunoprophylaxis failure of hepatitis B (HBV) remains a concern and has been reported in approximately 10-30% of infants born to highly viremic mothers with HBeAg-positive. Maternal HBV DNA >6log10 copies/mL (or 200,000 IU/mL) is the major independent risk for mother-to-child transmission (MTCT). Two recent random controlled trial (RCT) studies have shown that the use of Tenofovir Disoproxil Fumarate (TDF) in highly viremic HBsAg positive mothers may safely reduce the rate of MTCT when compared between groups of TDF treated and untreated patients. Tenofovir Alafenamide (TAF) is the successor to TDF, and both drugs have a similar mechanism of action to reduce HBV DNA levels and normalize serum alanine aminotransferase (ALT) in chronic hepatitis B patients (CHB) with few adverse effects. TAF however, has a better safety profile with less adverse effects to bone mineral density and renal function. The present prospective, double-arm study is to evaluate the non-inferiority in the efficacy and safety of TAF therapy versus TDF therapy in highly viremic mothers and their infants for the prevention of MTCT in the real world setting.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

This is a prospective, double-arm, multi-center study conducted through 11 centers across China. Consecutive 450 mothers who are eligible for the study will be enrolled during gestational weeks 24-28 to receive TDF or TAF based on the patients' preference, and the treatment will be discontinued right after the delivery. All infants will receive HBV vaccination plus HBIg within 12 hours after birth and the additional HBV vaccination at the age of 4 weeks and 24 weeks. Primary outcome assessment will be performed at the infants' age of 28 will be collected to evaluate non-inferiority in the safety and efficacy of TAF therapy versus TDF therapy. These parameters will be extracted from test results of serum biochemistries, hematology, and virology, including but not limited to aspartate aminotransferase (AST), ALT, HBV DNA levels, and serological status of HBV (HBsAg, HBeAb, HBcAb, HBeAg, and HBsAg).

All aforementioned clinical parameters will be extracted from mothers at the following timepoints for assessment: the baseline, i.e. the start of TAF/TDF treatment, gestational weeks 28, 32, 36, on delivery, and at postpartum weeks 24-28. For the infant, information from two timepoints, at birth and at infant age of 28 weeks, will be collected. This information regarding the infant will include the physical parameters weight, height, head circumference, HBV DNA levels, HBV serological status, if they received hepatitis B immunoglobin (HBIg), if they received the complete series of HBV vaccine. All relevant information regarding the patient will be logged into a password-protected computer for primary and secondary analysis.

Group A: 225 participating mothers will receive TAF (oral 25 mg tablet daily) starting at gestational week 24-28 of pregnancy and continue until delivery. The mothers will be followed together with their infants until postpartum week 28.Infants will receive hepatitis B vaccine plus HBIg at birth (within 12 hours) and additional hepatitis B vaccine at the age of week 4 and week 24. Group B: 225 participating mothers will receive TDF (oral 300 mg tablet daily) starting at gestational week 24-28 of pregnancy and continue until delivery. Patients in group B will have similar follow-up schedules as those in the Group A. Infants will receive hepatitis B vaccine plus HBIg at birth (within 12 hours) and additional hepatitis B vaccine at the age of week 4 and week 24.

Study Type

Observational

Enrollment (Anticipated)

450

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Chongqing
      • Shapingba, Chongqing, China
        • Recruiting
        • Pingdingshan Hospital of Chongqing Public Health Medical Treatment Center
        • Contact:
        • Principal Investigator:
          • Yuqing Wang, MD
        • Sub-Investigator:
          • Yangsu Tu, MD
    • Fujian
      • Fuzhou, Fujian, China
        • Recruiting
        • First Affiliated Hospital of Fujian Medical University
        • Contact:
        • Contact:
        • Principal Investigator:
          • Qi Zheng, MD
        • Sub-Investigator:
          • Xiao Y Lin, MS
    • Guangdong
      • Shenzhen, Guangdong, China
        • Recruiting
        • The Seventh Affiliated Hospital, Sun Yat-sen University
        • Contact:
        • Contact:
        • Principal Investigator:
          • You-Peng Chen, MD
        • Sub-Investigator:
          • Sai-Nan Pi, Ph.D
        • Sub-Investigator:
          • Bei-Bei Zhu, MD
    • Hainan
      • Haikou, Hainan, China
        • Recruiting
        • Hainan General Hospital
        • Contact:
        • Contact:
        • Principal Investigator:
          • Furong Xiao, MD
        • Sub-Investigator:
          • Biao Wu, MD
    • Hebei
      • Qinhuangdao, Hebei, China
        • Recruiting
        • The Third Hospital of Qinhuangdao
        • Contact:
        • Contact:
        • Principal Investigator:
          • Lihua Cao, MD
        • Sub-Investigator:
          • Shouyun Wang, MD
    • Heilonjiang
      • Harbin, Heilonjiang, China
        • Recruiting
        • The Fourth Hospital of Harbin Medical University
        • Contact:
        • Contact:
          • Linying Zhu, MD
          • Phone Number: (+86)13199561586
          • Email: zlyhmu@163.com
        • Principal Investigator:
          • Lei Yu, MD
        • Sub-Investigator:
          • Liying Zhu, MD
    • Hunan
      • Changsha, Hunan, China
        • Recruiting
        • Xiangya Hospital, Central South University
        • Contact:
        • Contact:
        • Sub-Investigator:
          • Zebing Huang, MD
    • Jiangxi
      • Ganzhou, Jiangxi, China
        • Recruiting
        • Ganzhou Fifth People's Hospital
        • Contact:
          • Huizhen Hong
          • Phone Number: (+86)13607964566
        • Contact:
          • Lijuan Long, MD
          • Phone Number: (+86)13766392668
        • Principal Investigator:
          • Lijuan Long, MD
        • Sub-Investigator:
          • Yuling Lan, MD
    • Liaoning
      • Shenyang, Liaoning, China
        • Recruiting
        • Shengjing Hospital Of China Medical University
        • Contact:
        • Contact:
        • Principal Investigator:
          • Qiuju Sheng, MD
        • Sub-Investigator:
          • Xiaoguang Dou, MD
    • Shanghai
      • Jinshan, Shanghai, China, 201508
        • Recruiting
        • Shanghai Public Health Clinical Center, Fudan University
        • Contact:
        • Contact:
        • Principal Investigator:
          • Min Liu, MD
        • Sub-Investigator:
          • Jing-hua Liu, MD
    • Zhejiang
      • Yuyao, Zhejiang, China
        • Recruiting
        • Yuyao People's Hospital of Zhejiang Province
        • Contact:
          • Lou Jian Jun, MD
          • Phone Number: (+86)15888019891
        • Contact:
          • Yu Hai Yun, MD
          • Phone Number: (+86)13505786411
        • Principal Investigator:
          • Lou Jian Jun, MD
        • Sub-Investigator:
          • Yu Hai Yun, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

225 consecutive chronically infected hepatitis B mothers who are willing to receive tenofovir alafenamide (TAF) treatment and another consecutive 225 who are willing to receive tenofovir disoproxil fumarate (TDF) treatment at eleven centers across China for high viremic load during pregnancy will be enrolled and followed prospectively for data collection. These patients underwent TAF/TDF treatment in their respective care centers and will be grouped together in Group A for TAF treatment and Group B for TDF treatment for primary and secondary analysis.

Description

Inclusion Criteria:

  1. Pregnant female, above 18 years of age and under 40 years of age.
  2. Gestational age between 12-14 weeks (The screening on patients can be started at gestational week 12).

  3. Documented compensated and stable chronic hepatitis B defined by all of the following:

    • HBsAg persistently positive > 6 months.
    • Clinical history, physical findings, and test results are compatible with compensated chronic hepatitis B.
  4. Detectable maternal serum HBsAg and HBeAg at the screening visit.
  5. Maternal serum HBV DNA levels exceeding 200,000 IU/mL by the COBAS Amplicor HBV PCR assay at screening visits.
  6. Patient is willing and able to comply with the study drug regimen and all other study requirements. Patient is also willing to prevent another pregnancy in 28 weeks after delivery of the current baby.
  7. Patient and her husband (both father and mother of the child) understand the risk and are willing to have the mother participating in the study. The mother must be willing and able to provide written informed consent to participate in the study.

Exclusion Criteria:

Patients will be excluded if they have any one of the following:

  1. Creatinine clearance <100 mL/min (using the Cockcroft-Gault method based on serum creatinine and ideal body weight) or hypo-phosphoremia (below normal range).
  2. History of renal events on adefovir or history of resistance to adefovir.
  3. Hemoglobin <8 g/dL, or neutrophil count <1000/uL, or ALT >5 times ULN, or total bilirubin >2 mg/dL; or albumin <25gm/L, or abnormal creatinine level, or abnormal BUN levels.
  4. History of abortion, or congenital malformation, or child infected with HBV in a prior pregnancy.
  5. Biological father of the child (current pregnancy) has CHB.
  6. Significant renal, cardiovascular, pulmonary, or neurological disease that may impact the subject's participation in the study as per the opinion of the investigator.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Arm (A) TAF Group Comprised of Patients from 11 Centers.
225 consecutive patients will be treated with local standard of care. The antiviral drug Tenofovir Alafenamide (TAF) will be used to treat highly viremic chronic hepatitis B mothers from the gestational week 24-28 of pregnancy to delivery of infant at eleven centers across the People's Republic of China (PRC). Infants will receive hepatitis B vaccine plus HBIg at birth (within 12 hours) and additional hepatitis B vaccine at the age of week 4 and week 24.
Drug: Tenofovir Alafenamide 25 MG for arm (A)
Tenofovir Alafenamide (TAF) will be provided, 25 mg Per Oral daily.
Other Names:
  • HBIg 200 IU im for infants
  • HBV vaccine 10 ug im for infants
Arm (B) TDF Group Comprised of Patients from 11 Centers.
225 consecutive patients will be treated with local standard of care. The antiviral drug Tenofovir Disoproxil Fumarate (TDF) will be used to treat highly viremic chronic hepatitis B mothers from the gestational week 24-28 of pregnancy to delivery of infant at eleven centers across the People's Republic of China (PRC). Infants will receive hepatitis B vaccine plus HBIg at birth (within 12 hours) and additional hepatitis B vaccine at the age of week 4 and week 24.
Drug: Tenofovir Disoproxil Fumarate 300mg for arm (B)
Tenofovir Disoproxil Fumarate (TDF) will be provided, 300 mg Per Oral daily.
Other Names:
  • HBIg 200 IU im for infants
  • HBV vaccine 10 ug im for infants

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessment on the Proportion of Infants who are Infected with Hepatitis B at the Age of 28 Weeks in the Two Groups
Time Frame: From the date of birth to the age of 24-28 weeks
Compare MTCT rates between the two study groups and demonstrate non-inferiority in efficacy. MTCT rate is defined as the proportion of infants with serum HBV DNA >20 IU/mL and/or HBsAg positivity at 28 weeks of age.
From the date of birth to the age of 24-28 weeks
Assessment on Congenital Defects and/or Malformation Rates in Each Infant Group for Comparison
Time Frame: from the date of birth to Infant's age of 24-28 weeks
The rate of congenital defects and/or malformation rates in infants. Congenital defects and/or malformation rates are defined as the proportion of infants with the aforementioned abnormalities discovered during the study period. The rate of infant congenital defect/malformation as determined in group A will be compared with that of group B.
from the date of birth to Infant's age of 24-28 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessment on the change in Maternal HBV DNA Levels at Delivery
Time Frame: from gestational week 24-28 week to delivery
Assess the change in maternal HBV DNA levels (IU/mL) at delivery when compared to the baseline before initiating TAF/TDF.
from gestational week 24-28 week to delivery
Maternal Serological Outcomes During the Study: Percentage of Mothers who Loss/Seroconversion of HBsAg or/and HBeAg During the Study
Time Frame: from gestational week 24-28 week to postpartum week 28
Assess the percentage of mothers who loss/seroconversion of HBsAg or/and HBeAg during the study. Loss is defined by a test showing a negative HBsAg/HBeAg result at the end of the trial, given a positive respective test result at baseline. A seroconversion is defined as a test showing a negative HBsAg and a positive HBsAb result, or a negative HBeAg and a positive HBeAb result at the end of the trial, given a positive HBsAg/HBeAg test result at baseline. The proportion of mothers who experience loss/seroconversion as determined in group A will be compared with that of group B.
from gestational week 24-28 week to postpartum week 28
Incidence of Treatment-Emergent Adverse Events in Mothers as Stratified by the CTCAE v 5.0
Time Frame: Gestational week 24-28 until Postpartum Week 28
Assess the percentage of Mothers who have adverse events during the study, graded by the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. The proportion of mothers who experience adverse events as determined in group A will be compared with that of group B.
Gestational week 24-28 until Postpartum Week 28
Incidence of Treatment-Emergent Adverse Events in Infants as Stratified by the CTCAE v 5.0
Time Frame: Delivery until Infant age Week 28
Assess the percentage of infants who have adverse events during the study, graded by the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. The proportion of infants who experience adverse events as determined in group A will be compared with that of group B.
Delivery until Infant age Week 28
Percentage of Mothers with Alanine transferase (ALT) Levels Within the Normal Limit
Time Frame: Gestational week 24-28 until Postpartum week 28
To calculate the percentage of mothers at postpartum 28 weeks whose ALT (U/L) levels stay within the normal limit in response to therapy. The proportion of mothers whose ALT levels who stay within the normal limit as determined in group A will be compared with that of group B.
Gestational week 24-28 until Postpartum week 28
Percentage of Mothers with Aspartamine transferase (AST) Levels Within the Normal Limit
Time Frame: Gestational week 24-28 until Postpartum week 28
To calculate the percentage of mothers at postpartum 28 weeks whose AST (U/L) levels stay within the normal limit in response to therapy. The proportion of mothers whose AST levels who stay within the normal limit as determined in group A will be compared with that of group B.
Gestational week 24-28 until Postpartum week 28
Group A: Proportion of Infants Born to Mothers Who Received TAF, Whose Physical Growth Characteristics Stay Within the Published National Normal Range.
Time Frame: Delivery to Infant age 28 weeks
Physical growth characteristics of the infants, born to mothers who received TAF, at the time points on birth and infant age of 24-28 weeks will be compared with the normal range of the national database published in recent years and analyzed. The proportion of infants whose growth characteristics are outside the published national range at the end of the study as determined in group A will be compared with that of group B.
Delivery to Infant age 28 weeks
Group B: Proportion of Infants Born to Mothers Who Received TDF, Whose Physical Growth Characteristics Stay Within the Published National Normal Range.
Time Frame: Delivery to Infant age 28 weeks
Physical growth characteristics of the infants, born to mothers who received TDF, at the time points on birth and infant age of 24-28 weeks will be compared with the normal range of the national database published in recent years and analyzed.The proportion of infants whose growth characteristics are outside the published national range at the end of the study as determined in group A will be compared with that of group B.
Delivery to Infant age 28 weeks
Tolerability of TDF vs TAF Therapy: Percentage of Mothers who Discontinue Therapy Due to the Adverse Event(s) During the Study.
Time Frame: Gestational week 24-28 until Delivery
Assess the percentage of mothers who discontinue therapy due to the adverse event(s) during the study. The proportion of mothers who discontinue therapy as determined in group A will be compared with that of group B.
Gestational week 24-28 until Delivery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

New Discovery LLC

Investigators

  • Principal Investigator: Calvin Pan, MD, Beijing Ditan Hospital, Capital Medical University; NYU Langone Health, NY, USA

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 27, 2020

Primary Completion (Anticipated)

September 30, 2021

Study Completion (Anticipated)

September 30, 2021

Study Registration Dates

First Submitted

December 6, 2019

First Submitted That Met QC Criteria

December 21, 2019

First Posted (Actual)

December 26, 2019

Study Record Updates

Last Update Posted (Actual)

December 29, 2020

Last Update Submitted That Met QC Criteria

December 25, 2020

Last Verified

December 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CN-P919-2020

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hepatitis B, Chronic

Clinical Trials on Tenofovir Alafenamide 25 MG for arm (A)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe